Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

By  

Acta Haematologica, Vol. 123, Iss. 4, 2010-04 ,pp. : 220-225

Karger

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 91-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

By Scalone Luciana   Mantovani Lorenzo G.   Krol Marieke   Rofail Diana   Ravera Simona   Grazia Bisconte Maria   Borgna-Pignatti Caterina   Borsellino Zelia   Cianciulli Paolo   Gallisai Domenico   Prossomariti Luciano   Stefàno Ippazio   Cappellini Maria D.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1905-1917

Informa Healthcare

Access to resources Recommend Favorite

Antihistone and Other Autoantibodies in β-Thalassemia major Patients Receiving Iron Chelators

By  

Acta Haematologica, Vol. 109, Iss. 1, 2002-12 ,pp. : 35-39

Karger

Access to resources Recommend Favorite